A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT04712097
Trial Phases:	Phase III	Protocol IDs:	GO42909 (primary) NCI-2021-09247 2020-005239-53
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT04712097

Summary

This study will evaluate the efficacy and safety of mosunetuzumab in combination with
lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len)
in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have
received at least one line of prior systemic therapy.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.